44754 Federal Register / Vol. 73, No. 148 / Thursday, July 31, 2008 / Notices 

Licensing Contact: Adaku 

Nwachukwu, J.D.; 301/435–5560; 

madua@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute, Center for 

Cancer Research, Laboratory of 

Molecular Pharmacology, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize inhibitors of TyrosylDNA phosphodiesterase (Tdp1). Please 

contact John D. Hewes, PhD at 301–435–

3121 or hewesj@mail.nih.gov for more 

information. 

Dated: July 22, 2008. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–17506 Filed 7–30–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Methods for Promoting Stem Cell 

Proliferation and Survival 

Description of Technology: 

Regenerative medicine has the potential 

to treat numerous human diseases and 

afflictions including neurodegenerative 

disorders and spinal cord injury that are 

typically insidious and worsen over 

time. This technology consists of a 

promising treatment method that coaxes 

stem cells into a state that promotes 

survival and proliferation. Two critical 

elements of this approach involve 

identifying the target niche and 

determining the pharmacological agents 

that can be used to promote stem cell 

regeneration. 

Specifically, this technology consists 

of a method to activate the endogenous 

neural stem cells (NSCs) to promote 

their survival and yield using 

angiopoietin-2 and a cocktail of ligands 

and growth factors. This method has 

demonstrated that it can significantly 

improve the yield of stem cell cultures 

in vitro and stimulate behavioral 

recovery in a model of Parkinson’s 

disease in vivo. This method is 

applicable to a variety of stem cell types 

including embryonic stem cells, adult 

spinal cord cells, and pericyctes from 

blood vessels. 

Possible Applications: 

• Method for culturing stem cells for 

optimal regeneration. 

• Treatment of neurological diseases 

and disorders such as Parkinson’s 

disease, stroke, diabetes-related 

neuropathies, and spinal cord. 

• Diagnostic assays to determine 

proliferation or inhibition of stem cells. 

Development Status: Pre-clinical. 

Inventors: Andreas AndroutsellisTheotokis and Ronald D.G. McKay 

(NINDS). 

Relevant Publication: A 

Androutsellis-Theotokis, RR Leker, F 

Soldner, DJ Hoeppner, R Ravin, SW 

Poser, MA Rueger, SK Bae, R Kittappa, 

RD McKay. Notch signaling regulates 

stem cell numbers in vitro and in vivo. 

Nature. 2006 Aug 17;442(7104):823–

826. 

Patent Status: U.S. Provisional 

Application No. 60/965,094 filed 16 

Aug 2007 (HHS Reference No. E–182–

2007/0–US–01) 

Licensing Status: Available for 

licensing. 

Licensing Contact: Fatima Sayyid, 

M.H.P.M.; 301–435–4521; 

Fatima.Sayyid@nih.hhs.gov 

Collaborative Research Opportunity: 

The National Institute of Neurological 

Disorders and Stroke is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize agents with activity on 

proliferation and/or differentiation of 

stem cells. Please contact Laurie Arrants 

at 301–435–3112 or 

ArrantsL@ninds.nih.gov or Martha 

Lubet at 301–435–3120 or 

lubetm@mail.nih.gov for more 

information. 

Treatment of Alcoholism by Inhibition 

of the Neuropeptide Y Receptor 

Description of Technology: Aversive 

or anticraving medications are currently 

used to supplement behavioral 

treatment of alcohol dependence. 

However, there is a need for developing 

more effective medications than those 

available. Neuropeptide Y (NPY) is a 

neurotransmitter known for increasing 

appetite and possibly having a role in 

alcohol preference and dependence. 

This is likely to be mediated by 

activation of the post-synaptic NPY–Y1 

receptor, but developing molecules 

suitable for human therapeutics that 

activate that receptor represents a major 

challenge. Researchers at the NIH have 

now shown that administering 

antagonists of the presynaptic Y2 

receptor of NPY decreases alcohol 

consumption and may be a valuable 

new treatment for alcoholism. 

Applications: Treatment of alcohol 

dependence. 

Market: In the United States, 17.6 

million people—about l in every 12 

adults—abuse alcohol or are alcohol 

dependent. It is estimated that on any 

given day, more than 700,000 people in 

the United States receive alcoholism 

treatment. Consequently, billions of 

dollars are spent in the treatment, 

prevention, and support of persons 

suffering from alcoholism. Moreover, 

the economic loss attributed to alcohol 

abuse and alcoholism is in the trillions. 

Development Status: Early stage. 

Inventors: Markus Heilig (NIAAA) et 

al. 

Publications: 

1. R Rimondini et al. Suppression of 

ethanol self-administration by the 

neuropeptide Y (NPY) Y2 receptor 

antagonist BIIE0246: Evidence for 

sensitization in rats with a history of 

dependence. Neurosci Lett. 2005 Feb 

28;375(2):129–133. 

2. A Thorsell et al. Blockade of central 

neuropeptide Y (NPY) Y2 receptors 

reduces ethanol self-administration in 

rats. Neurosci Lett. 2002 Oct 

25;332(1):1–4. 

Patent Status: U.S. Patent Application 

10/492,785 filed 17 May 2004 (HHS 

Reference No. E–101–2004/0–US–03); 

Swedish Patent Application 0103476–8 

filed 18 Oct 2001 (HHS Reference No. 

E–101–2004/0–SE–01) 

Licensing Status: Available for 

licensing. 

Licensing Contact: Norbert Pontzer, 

JD, PhD; 301–435–5502; 

pontzern@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute on Alcohol Abuse 

and Alcoholism, Laboratory of Clinical 

and Translational Studies is seeking 


jlentini on PROD1PC65 with NOTICES
Federal Register / Vol. 73, No. 148 / Thursday, July 31, 2008 / Notices 44755 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize antagonism of 

presynaptic NPY Y2 receptors for 

treatment of alcohol dependence. Please 

contact Peter B. Silverman at 

psilverm@mail.nih.gov for more 

information. 

Dated: July 22, 2008. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–17508 Filed 7–30–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Center for Scientific 

Review Special Emphasis Panel, July 23, 

2008, 8 a.m. to July 24, 2008, 6 p.m., 

National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

which was published in the Federal 

Register on July 1, 2008, 78 FR 37469. 

The meeting will be held August 14, 

2008 to August 15, 2008. The meeting 

time and location remains the same. 

The meeting is closed to the public. 

Dated: July 23, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E8–17518 Filed 7–30–08; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Mosquito 

Vectors. 

Date: August 19, 2008. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Fouad A. El-Zaatari, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3206, 

MSC 7808, Bethesda, MD 20814–9692, (301) 

435–1149, elzaataf@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Musculoskeletal Tissue/Cell Biology. 

Date: August 20, 2008. 

Time: 1:15 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: John P. Holden, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4211, 

MSC 7814, Bethesda, MD 20892, 301–496–

8551, holdenjo@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Nursing 

Science. 

Date: August 29, 2008. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Ann Hardy, DRPH, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3158, 

MSC 7770, Bethesda, MD 20892, (301) 435–

0695, hardyan@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Multiscale 

Models of the Physiome. 

Date: September 17, 2008. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Carlyle Suites, 1731 New 

Hampshire Avenue, NW., Washington, DC 

20009. 

Contact Person: Malgorzata Klosek, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4188, 

MSC 7849, Bethesda, MD 20892, (301) 435–

2211, klosekm@csr.nih.gov. 

Name of Committee: Musculoskeletal, Oral 

and Skin Sciences Integrated Review Group; 

Oral, Dental and Craniofacial Sciences Study 

Section. 

Date: September 23–24, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Westin Washington, DC City 

Center, 1400 M Street, NW., Washington, DC 

20005. 

Contact Person: Tamizchelvi Thyagarajan, 

PhD, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4016K, 

MSC 7814, Bethesda, MD 20892, 301–451–

1327, tthyagar@csr.nih.gov. 

Name of Committee: Digestive Sciences 

Integrated Review Group; Xenobiotic and 

Nutrient Disposition and Action Study 

Section. 

Date: September 24, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Patricia Greenwel, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2174, 

MSC 7818, Bethesda, MD 20892, 301–435–

1169, greenwep@csr.nih.gov. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group; Auditory System 

Study Section. 

Date: September 24–25, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: One Washington Circle Hotel, One 

Washington Circle, Washington, DC 20037. 

Contact Person: Lynn E. Luethke, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5166, 

MSC 7844, Bethesda, MD 20892, (301) 435–

1018, luethkel@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Pathophysiological Basis of Mental Disorders 

and Addictions. 

Date: September 25, 2008. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Boris P. Sokolov, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5217A, 

MSC 7846, Bethesda, MD 20892, 301–435–

1197, bsokolov@csr.nih.gov. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group; Cognitive 

Neuroscience Study Section. 

Date: September 25, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington Embassy Row, 

2015 Massachusetts Avenue, NW., 

Washington, DC 20036. 

Contact Person: Judith A. Finkelstein, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5178, 

MSC 7844, Bethesda, MD 20892, 301–435–

1249, finkelsj@csr.nih.gov. 


jlentini on PROD1PC65 with NOTICES